Vera Therapeutics (VERA) Cash from Financing Activities (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Cash from Financing Activities data on file, last reported at $3.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 157.14% year-over-year to $3.9 million; the trailing twelve-month figure through Mar 2026 stood at $311.3 million (down 6.14% YoY), and the FY2025 full-year result was $308.9 million, down 49.08% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $3.9 million, down from $286.3 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $326.0 million in Q4 2024 and bottomed at $48000.0 in Q2 2022.
• The 5-year median for Cash from Financing Activities is $3.9 million (2026), against an average of $67.9 million.
• Peak annual rise in Cash from Financing Activities reached 286771.43% in 2022, while the deepest fall reached 99.9% in 2022.
• A 5-year view of Cash from Financing Activities shows it stood at $20.7 million in 2022, then increased by 19.89% to $24.8 million in 2023, then jumped by 1212.85% to $326.0 million in 2024, then decreased by 12.17% to $286.3 million in 2025, then slumped by 98.62% to $3.9 million in 2026.
• The last three Cash from Financing Activities figures came in at $3.9 million (Q1 2026), $286.3 million (Q4 2025), and $797000.0 (Q3 2025), per Business Quant data.

Peer Comparison